Perspective Therapeutics (CATX) Interest & Investment Income (2010 - 2026)
Perspective Therapeutics (CATX) reported Interest & Investment Income of $2.2 million for Q1 2026, down 7.84% on a YoY basis from $2.4 million in Q1 2025, and down 72.36% sequentially from $7.9 million in Q4 2025.
Perspective Therapeutics (CATX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 17 years of Interest & Investment Income data on file, last reported at $2.2 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 7.84% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (down 20.61% YoY), and the FY2025 full-year result was $8.1 million, down 22.83% from the prior year.
- Interest & Investment Income fell to $2.2 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $10.5 million in Q4 2024 to a low of -$16000.0 in Q2 2025.
- A 5-year average of $1.8 million and a median of $249000.0 in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income slumped 88.95% in 2023 and soared 16859.68% in 2024, its largest moves.
- Tracing CATX's Interest & Investment Income over 5 years: stood at $561000.0 in 2022, then tumbled by 88.95% to $62000.0 in 2023, then soared by 16859.68% to $10.5 million in 2024, then retreated by 24.4% to $7.9 million in 2025, then tumbled by 72.36% to $2.2 million in 2026.
- Business Quant data shows CATX's Interest & Investment Income at $2.2 million in Q1 2026, $7.9 million in Q4 2025, and $111000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 106.00 Mn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | - |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 33.50 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | - |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 40.98 Mn |
| 10 | Perspective Therapeutics | 294.24 Mn | 294.24 Mn | - | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.20 Mn |
| Dec 31, 2025 | 7.95 Mn |
| Sep 30, 2025 | 111,000.00 |
| Jun 30, 2025 | -16,000.00 |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 10.52 Mn |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | 204,000.00 |
| Jun 30, 2023 | 294,000.00 |
| Mar 31, 2023 | 374,000.00 |
| Dec 31, 2022 | 561,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Dec 31, 2021 | 31,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |